Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.
about
Diagnosis and management of the primary headache disorders in the emergency department settingAcute migraine: Current treatment and emerging therapiesHeadache management: pharmacological approachesOrofacial pain management: current perspectives.Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.Migraine pathogenesis and state of pharmacological treatment optionsSingle-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot programSumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisalHeadache-type adverse effects of NO donors: vasodilation and beyondTherapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis.The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult SubjectsAlmotriptan and zolmitriptan in the acute treatment of migraine.CGRP receptor antagonists: an expanding drug class for acute migraine?Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache.Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis.Migraine and risk of stroke in older adults: Northern Manhattan Study.Eletriptan in migraine.Migraine treatment throughout the lifecycle.Migraine, cerebrovascular disease and the metabolic syndromeCan we develop neurally acting drugs for the treatment of migraine?Rizatriptan in migraine.Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan.The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.Optimizing migraine therapy: evidence-based and patient-centered care.Sumatriptan: update and review.Migraine: emerging treatment options for preventive and acute attack therapy.Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment.Treatment-emergent CNS symptoms following triptan therapy are part of the attack.Understanding the causes and prevention of menstrual migraine: the role of estrogen.Current migraine management - patient acceptability and future approaches.Migraine and cardiovascular disease: possible mechanisms of interactionTriptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular RiskTriptans and troponin: a case reportSumatriptan/naproxen sodium combination for the treatment of migraine.The pharmacological management of migraine, part 1: overview and abortive therapy.Randomized, controlled trial of telcagepant for the acute treatment of migraine.Migraine in the triptan era: progresses achieved, lessons learned and future developments.Calcitonin gene-related peptide receptor antagonists for migraine.Headache and cardiovascular disease: old symptoms, new proposals.
P2860
Q24651176-2A8141FB-5CE0-4873-BFCE-B7AF644F28A1Q24654649-FF7C4171-9B3C-4E37-9578-D28B2575E155Q27316751-43B381A1-FC88-46D1-9BFD-6A7EFE60DFE7Q30442178-5176D180-A702-4B84-AF6E-4B00EB2C829FQ30660036-32A6C6C8-524C-45F3-B0C5-670367143CECQ30886663-17F3CE69-BCFA-4FF0-BE49-EB3972014A92Q30968082-76CE0F7C-4253-46DA-B4FD-AAEE86E0BE40Q33755782-BDA34015-95C9-4BD1-8027-DD8C5702CDFAQ33812736-19A2945F-30E8-44AD-8007-9C18808D2CB7Q34094599-B71E8881-DB9B-43E1-8712-BD0705A0FBFFQ34462428-0DE12AAD-B57F-482D-B3A2-BC2B2C44CBF4Q34573136-E6DCF295-B9E5-4C46-BB94-2CFA7808D8A5Q34637610-B2062C75-FDCB-4976-B308-70BCC3F03916Q35684215-F7F824C3-EA6B-4C77-97DA-A769B1AD7D4CQ35884646-C6D9DD4B-2F21-4C33-85FD-C83768DB4B51Q36005662-0BE80893-2FAE-4D88-8854-11BC451A4A39Q36106757-78DD32F1-5105-4CAB-988B-AB634389F120Q36153372-EC0F48AD-AA49-4204-981C-D335EB35E200Q36239499-65AE9934-547E-4B8D-B0B7-FCEA5AB65009Q36240187-3275A09A-1FF1-4044-B2C1-7DE76F7C97D5Q36257191-9D77EB17-D6EB-48AE-8C96-43AD5626CD8FQ36260631-E83FAEF8-3AC0-4DA8-B6AC-73AF3FAA0603Q36340711-5432366E-20E2-49F2-A8DA-3BF889E58EEEQ36342969-B7568B25-6B2C-4A8E-B195-45B6204651A2Q36511332-A105694A-F0F3-46CC-99D8-7E6319DE900CQ36543148-5DEC6D6F-BDDA-42E0-8FEA-C1AE3988118EQ36580576-FABF29A5-52A5-421E-AB9E-198B10817017Q36625038-40FBA7C9-6975-4E1A-88E7-CEE68F152B30Q36768331-BB88B2D6-EC93-433A-A0E5-364C38D815B4Q36938684-7942FA17-90A9-4D5F-AF18-566050136280Q37106936-7D4C56E9-61DC-42C5-93E2-6007A5A3BD3CQ37213760-87693068-F9E8-45A1-83AA-FC39A66B4452Q37218677-D36457DA-9720-4384-B3F5-E3CAA028D13AQ37251602-76C43A79-88EA-4E44-8B4C-DEA2F44E8BBEQ37256688-AC560D32-A1E2-427C-BAB4-14FAC859575EQ37340160-9C86902C-67AB-4336-9185-9201BDAB80E1Q37368387-E605F207-1AE7-4F37-8054-CA0E2CFA5C5AQ37558323-F9F891ED-1611-4768-85ED-4B675D4322F5Q37756158-804B221A-B6E5-4CDC-B190-48A5291AB3B7Q37798812-0EE9D09F-4860-46A0-BA14-6242BE93E2C2
P2860
Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Consensus statement: cardiovas ...... e acute treatment of migraine.
@ast
Consensus statement: cardiovas ...... e acute treatment of migraine.
@en
type
label
Consensus statement: cardiovas ...... e acute treatment of migraine.
@ast
Consensus statement: cardiovas ...... e acute treatment of migraine.
@en
prefLabel
Consensus statement: cardiovas ...... e acute treatment of migraine.
@ast
Consensus statement: cardiovas ...... e acute treatment of migraine.
@en
P2093
P2860
P50
P1433
P1476
Consensus statement: cardiovas ...... e acute treatment of migraine.
@en
P2093
Antoinette MaassenVanDenBrink
David Matchar
Hassan Loutfi
Jane Saiers
K Michael Welch
R Allan Purdy
Steven Hahn
Susan Hutchinson
Timothy R Smith
Triptan Cardiovascular Safety Expert Panel
P2860
P304
P356
10.1111/J.1526-4610.2004.04078.X
P577
2004-05-01T00:00:00Z